AURA

6.8701.58%
NC

Natalie C. Holles

President, CEO & Director

Ms. Natalie C. Holles is Independent Director of LeonaBio, Inc. from May 5, 2026. Ms. Natalie C. Holles is President, CEO & Director of Aura Biosciences, Inc. from April 30, 2026. Ms. Holles served as Chief Executive Officer since August 9, 2021 until December 2025 and Director of Third Harmonic Bio, Inc. since August 2021. She was an Independent Director at Allakos Inc. since December 2020 until August 2021. She was Lead Independent Director at Day One Biopharmaceuticals, Inc. until 2022 and had been its Independent Director since February 2021 until April 23, 2026. She serves as Independent Director of Day One Biopharmaceuticals Holding Co LLC. since February 2021 and serves its Lead Independent Director. She had been a Director of Rubius Therapeutics, Inc. since March 25, 2019 until August 09, 2022. Ms. Holles served as President and Chief Executive Officer of Audentes Therapeutics, Inc. (a subsidiary of Astellas Pharma, Inc.) from January 2020 to March 2022 and serves as its Director. Prior to this, Ms. Holles served Audentes as Senior Vice President and Chief Operating Officer from August 2015 to May2018 and President and Chief Operating Officer from May2018 to January 2020. Ms. Holles served as Senior Vice President of Corporate and Business Development at Hyperion Therapeutics, Inc. from July 2013 to May 2015(acquired by Horizon Pharma in 2015). From August 2012 until June 2013, she served as an Executive Vice President of Corporate Development at Immune Design, Inc., a leading cancer immunotherapy company based in Seattle. Ms. Holles provided executive-level strategy and business development advisory services to several privately held biopharmaceutical companies from December 2010 to June 2013 as an independent life sciences corporate development consultant. She served as the Vice President of Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012). She held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. She began her career in the industry as a Marketing Planning Associate at Genentech, Inc. She has corporate development, strategic planning and commercial experience, gained in a range of therapeutic areas and with a focus on orphan diseases. She was a Howard Hughes Medical Institute Predoctoral Fellow. Ms. Holles received her M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder and her B.A. in Human Biology from Stanford University.

Positions